Latest Accounting News

Sabre Resources advances exploration with promising uranium targets in the Northern Territory and copper-gold anomalies in Western Australia, setting the stage for upcoming drilling campaigns.

Jayride Group reports a sharp decline in bookings amid supplier payment challenges but eyes growth through API technology and cost cuts.

Cambium Bio has secured a A$3 million capital raise and achieved FDA Fast Track status for its lead ophthalmology product, Elate Ocular®, setting the stage for Phase 3 trials in mid-2025.

Fatfish Group reported a 20% increase in cash receipts to A$0.76 million for Q4 2024, driven by advances in its AI gaming subsidiary, but rising operating expenses led to a net cash outflow of A$0.37 million.

True North Copper Limited reported a significant cash outflow in the December 2024 quarter, driven by high operating expenses linked to voluntary administration and exploration activities. Despite ending the quarter with $19.12 million in cash, the company’s negative operating cash flow signals ongoing financial pressure.

Electro Optic Systems has completed the sale of EM Solutions for $158.6 million, exceeding initial valuations, and fully repaid its debt to Washington H. Soul Pattinson, leaving the company debt-free with a strong cash position.

Ark Mines Ltd reported a significant cash outflow in its December 2024 quarter, prompting plans for a capital raising to support ongoing exploration activities.

Freehill Mining Ltd’s December quarter cash flow report reveals a $114,000 net cash outflow from operations but highlights a solid liquidity position with $301,000 in unused financing facilities.

Papyrus Australia Ltd reported a $284,000 net cash outflow for the December 2024 quarter, reflecting abnormal expenses but maintaining a solid funding runway through existing facilities and strategic initiatives.

ReNu Energy reports progress on a management buyout proposal for its hydrogen subsidiary and completes sale of legacy geothermal assets, signaling a strategic pivot and ongoing capital challenges.

Excite Technology Services has achieved positive EBITDA in December 2024, driven by strong revenue growth and record customer receipts, notably from its Digital Forensics division and the integration of CDFS.

Arovella Therapeutics has bolstered its financial position with a $20 million placement, fully funding the Phase 1 clinical trial of its lead CAR-iNKT therapy, ALA-101, targeting CD19-positive blood cancers. The company also established a Clinical Advisory Board and anticipates key regulatory and clinical milestones in 2025.